China Chronic Obstructive Pulmonary Disease Registration Research

Overview

With the comparative effectiveness research methods and hospital registration study approach, the purpose of this study is to objectively record the methods, efficacy and its influencing factors of COPD commonly used treatment methods/programs (Western medicine, Traditional Chinese Medicine and Integrative Medicine) in the actual medical environment, analysis of application characteristics for the different programs, and provide the basis for its revision and promotion. It is a first registration study for COPD in China.

Full Title of Study: “Transformation and Application of Diagnosis and Treatment Programs for COPD Based on Chronic Obstructive Pulmonary Disease Registration Research in China”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2018

Detailed Description

Chronic obstructive pulmonary disease (COPD) is a major disease of harm public health seriously. Although different treatment methods / programs (Western medicine, Traditional Chinese Medicine and Integrative Medicine) exist and are being developed to relieve symptoms and reduce mortality in COPD, most have only been studied in randomized controlled trials (RCT).

Most RCT study patients usually require a single disease, the use of standard treatment and a single intervention to evaluate interventions in an ideal state can achieve maximum effect,that is theoretical effect, it is difficult to provide the evidence of practical clinical efficacy or effectiveness. Secondly, RCT often require strict inclusion and exclusion criteria, resulting in inadequate representation of the study, thus limiting its conclusions spread to overall. There are some challenges for different treatment methods on the actual effect of the patients in the evaluation of conventional medical practice with RCT.

Real World Research based on clinical practice pay close attention highly in response to these problems, and the registry study had been applied widely in clinical practice. With the comparative effectiveness research methods and hospital registration study approach, based on the classes of medications recommended by 2014 GOLD and Chinese Treatment Guidelines for COPD, the purpose of this study is to objectively record the methods, efficacy and its influencing factors of COPD commonly used treatment methods/programs (Western medicine, Traditional Chinese Medicine and Integrative Medicine) in the actual medical environment, analysis of application characteristics for the different programs, and provide the basis for its revision and promotion. This is a first registration study for COPD in China.

Arms, Groups and Cohorts

  • Western medicine
    • Patients in this group only choose conventional medicine treatment based on the classes of medications recommended by 2015 GOLD for COPD.
  • Traditional Chinese Medicine
    • Patients in this group only choose conventional medicine treatment based on the Chinese Treatment Guidelines for COPD.
  • Integrative Medicine
    • Patients in this group choose western medicine and Traditional Chinese Medicine.

Clinical Trial Outcome Measures

Primary Measures

  • The frequency of exacerbation
    • Time Frame: Change from Baseline in the frequency of exacerbation at the months 3, 6, 9, 12, 15, 18, 21 and 24.

Secondary Measures

  • all cause mortality
    • Time Frame: through study completion, an average of 1 year
  • Forced expiratory volume in one second,FEV1
    • Time Frame: Change from Baseline in the FEV1 at the months 6, 12, 18 and 24.
  • Dyspnea
    • Time Frame: Change from Baseline in the mMRC at the months 3, 6, 9, 12, 15, 18, 21 and 24.
    • Using modified british medical research council (mMRC) to assess the degree of dyspnea in patients with COPD, and how this changes over time.
  • Symptoms
    • Time Frame: Change from Baseline in the CAT at the months 6, 12, 18 and 24.
    • Using the COPD Assessment Test (CAT) as a comprehensive measure of symptoms.
  • Quality of life
    • Time Frame: Change from Baseline in the SF-36 at the months 6, 12, 18 and 24.
    • Using the Chinese version of the 36-item Short Form Health Survey (SF-36) to measure quality of life.

Participating in This Clinical Trial

Inclusion Criteria

  • A confirmed diagnosis of COPD.
  • With the informed consent signed.

Exclusion Criteria

  • Pregnant or breast-feeding women.
  • Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study .
  • Malignancy for which patient has undergone resection, radiation therapy or chemotherapy within the last 5 years.
  • Complicated with respiratory disorders other than COPD (e.g., lung fibrosis, pulmonary thromboembolic).
  • Complicated with heart failure (NYHA Class III or IV),or myocardial infarction within six months.
  • Complicated with serious hepatic and renal diseases (liver cirrhosis, portal hypertension, bleeding of varicose veins, dialysis, or renal transplantation).

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Henan University of Traditional Chinese Medicine
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jiansheng Li, doctor, Study Chair, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.